BNTX News and Press, BioNTech SE From 02/17/23

Summary The COVID-19 public health emergency is coming to end in May 2023. As a result, Moderna, Inc. is approaching a long earnings trough after a couple years of mind-blowing growth. The market is going to hyper-fixate on the expected year-over-year declines in earnings in the upcomin...

It's often said that near-term fluctuations in the stock market are mostly based on noise rather than fundamentals. Shares of Pfizer (NYSE: PFE) have tumbled 15% year to date even as the S&P 500 index has rallied 7%. This raises the question: Is this recent weakness in the p...

Summary The significant drop of over 20% from December highs to last week's lows left PFE investors nursing their wounds. Pfizer's underwhelming FY23 outlook still fell short of downgraded analysts' estimates. With the reset in forward expectations, weak holders have likely fled, ig...

All Australian adults will be able to receive a fifth COVID-19 vaccine dose later this month, the country’s health minister, Mark Butler, announced Wednesday. “From February 20, all adults who have not had a COVID-19 booster or a confirmed case in the past six months can now get...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Undervalued growth stocks  are often overlooked by investors, they can offer significant potential for capital appreciation. One way to identify undervalued growth stocks is to look for companies with high revenue an...

Summary April 26 is FDA decision day for SER-109, the Seres microbiome treatment for recurrent C. difficile infection. Finch Therapeutics gives up on Phase 3 trial for C. difficile recurrence; lays off 95% of staff. FNCH is a casualty of setbacks at the beginning of the new medical ...

Last week, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the Food and Drug Administration (FDA) recommended a move toward a uniform yearly formula for all COVID-19 vaccines, regardless of whether they're used as primary shots or as boosters. Medical experts would cho...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips You don’t have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical scien...

BioNTech ( NASDAQ: BNTX ) has completed the building of its first plasmid DNA manufacturing facility in Marburg, Germany. Plasmid DNA are the building blocks for the manufacturing of mRNA-based vaccines and therapies, as well as cell therapies. The new plant will be used...

Plasmids are an important starting material for the manufacturing of mRNA- and cell-based drugs The new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in manufacturing an important starting material for its oncology and COVID-19 vaccine pipeline...